Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The company's focus is on being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
Last trade$22.31
Day change-$2.68 (-10.72%)
Day range$22.08 – $26.06
Volume106,927
Market cap$427M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$426.7M
Price / earnings
—
Price / book
-1.23×
Price / sales
0.42×
EV / sales
5.09×
EV / EBITDA
10.26×
Profitability
Earnings per share
-$16.11
Return on assets
-5.88%
Return on equity
79.38%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-13.75×
Current ratio
1.15×
Quick ratio
1.15×
Cash ratio
0.05×
Cash flow
Price / cash flow
3.25×
Price / free cash flow
—
Free cash flow
-$27.82M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CTEV, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Revenue
$268.31M
$257.48M
$244.68M
$246.55M
$245.96M
$241.57M
$231.33M
Cost of revenue
$69.77M
$67.67M
$69.08M
$70.09M
$62.06M
$60.82M
$60.44M
Gross profit
$198.54M
$189.81M
$175.6M
$176.46M
$183.9M
$180.75M
$170.89M
Selling, general and administrative
$66.33M
$55.39M
$57.83M
$56.05M
$60M
$51.12M
$46.97M
Research and development
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$177.8M
$166.09M
$168.92M
$167.79M
$171.94M
$162.35M
$157.49M
Operating income
$20.73M
$23.72M
$6.68M
$8.67M
$11.96M
$18.4M
$13.41M
Interest expense
-$100.9M
-$100.25M
-$99.54M
-$99.41M
-$101.23M
-$99.75M
-$91.64M
Income before taxes
-$80.03M
-$76.65M
-$92.72M
-$106.92M
-$93.36M
-$82.93M
-$89.87M
Income taxes
-$18.24M
-$17.42M
-$19.16M
-$26.35M
-$23.61M
-$20.29M
-$18.55M
Net income
-$61.79M
-$59.23M
-$73.56M
-$80.57M
-$69.75M
-$62.64M
-$71.32M
Net income attributable to common shareholders
-$61.78M
-$59.23M
-$73.56M
-$80.57M
-$69.75M
-$62.64M
-$71.32M
EBITDA
$132.21M
$134.42M
$117.77M
$120.41M
$123.9M
$129.63M
$123.93M
Basic earnings per share
-$3.64
-$3.49
-$4.41
-$4.87
-$4.23
-$3.81
-$4.38
Diluted earnings per share
-$3.64
-$3.49
-$4.41
-$4.87
-$4.23
-$3.81
-$4.38
Recent news
Company coverage with links to the original publishers.
Claritev Corporation reported a quarterly loss of $3.64 per share, slightly beating consensus estimates of $3.68 loss, with revenues of $268.31 million exceeding expectations by 4.51%. However, the stock has underperformed significantly, down 46.9% year-to-date versus the S&P 500's 7.8% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Claritev reported Q3 2026 revenues of $268.3 million, up 9.1% year-over-year, with Adjusted EBITDA of $162.0 million. Despite a net loss of $61.8 million, the company raised its full-year 2026 guidance and provided preliminary 2027 revenue expectations of $1.1 billion. The company highlighted growth across solutions and verticals, AI innovation initiatives, and new product launches including Transparency-Based Pricing.
Fulgent Genetics reported a Q3 loss of $0.09 per share, significantly beating the consensus estimate of a $0.65 loss, representing an 86.15% earnings surprise. Revenue reached $90.41 million, surpassing estimates by 4.77%. However, the stock has underperformed the market by 25.1% year-to-date. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Omnicell reported Q3 2026 earnings of $0.58 per share, beating consensus estimates of $0.42 by 38.10%, with revenues of $307.85 million slightly exceeding expectations. However, the stock has underperformed the S&P 500 by 33.7% year-to-date. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical Info Systems industry ranks in the top 38% of Zacks industries.
Tempus AI (TEM) shares gained 17.9% over the past month, outperforming peers like Claritev and iRhythm, driven by strong demand for healthcare AI. The company reported 28% revenue growth in its Data and Applications segment to $93.2M in Q2, with Insights revenues up 36%. However, TEM trades at a premium valuation of 6.59X sales versus the industry average of 4.70X, and its growth depends heavily on regulatory approvals and reimbursement decisions. Analysts recommend current holders maintain positions while prospective investors wait for a more favorable entry point.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.